ER-100 targets glaucoma and NAION through epigenetic reprogramming, with Phase II trials advancing, highlighting potential economic and healthcare disruptions in anti-aging therapies. Life Biosciences...
Life Biosciences receives FDA clearance for the first human trial of cellular reprogramming targeting glaucoma and NAION, signaling regulatory openness to longevity therapies and potential vision rest...
